Gout is the most common form of inflammatory arthritis in adults, affecting approximately 9.2 million Americans. It results from the deposition of monosodium urate (MSU) crystals in joints and soft tissues when serum uric acid rises above its saturation threshold. The hallmark presentation — sudden, severe pain in the first metatarsophalangeal (MTP) joint (podagra) waking a patient from sleep — is immediately recognizable. Nurses encounter gout across emergency departments, medical-surgical floors, primary care, and long-term care settings. Managing the acute flare demands rapid, targeted pharmacologic intervention. Long-term management requires sustained urate-lowering therapy (ULT), dietary modification, and patient education about a disease that patients frequently mismanage. This reference page covers gout pathophysiology, clinical presentation, diagnosis, pharmacology, nursing diagnoses, interventions, and patient education in depth.
Fast-scan summary: key gout facts
| Parameter | Key facts |
|---|---|
| Cause | Monosodium urate (MSU) crystal deposition from sustained hyperuricemia (>6.8 mg/dL in women, >7.0 mg/dL in men) |
| Classic presentation | Podagra — sudden, excruciating pain in first MTP joint, nocturnal onset, erythema, warmth, swelling |
| Gold-standard diagnosis | Synovial fluid analysis: negatively birefringent, needle-shaped crystals under polarized light microscopy |
| Serum uric acid caveat | May be normal or low during an acute flare — a normal level does NOT rule out gout |
| Acute flare treatment | Colchicine (first-line), NSAIDs (indomethacin), or corticosteroids (when others contraindicated) |
| Urate-lowering therapy | Allopurinol (xanthine oxidase inhibitor, first-line); target uric acid <6.0 mg/dL; never start during acute flare |
| Critical medication fact | ULT can precipitate flares on initiation — patients must not stop it; colchicine prophylaxis given for 3–6 months |
| Dietary triggers | Organ meats, shellfish, red meat, alcohol (especially beer); fructose-sweetened beverages |
| Protective foods | Low-fat dairy, cherries/cherry juice, vitamin C, coffee (moderate consumption) |
| Key nursing priorities | Pain control, joint rest, hydration, medication education, trigger avoidance, renal function monitoring |
Pathophysiology
Purine metabolism and uric acid synthesis
Uric acid is the end product of purine catabolism in humans. Purines — adenine and guanine — are nitrogen-containing bases found in DNA, RNA, and high-energy molecules like ATP. They are obtained both from endogenous cell turnover (roughly 65–70% of total uric acid production) and from dietary intake of purine-rich foods (30–35%).
The metabolic pathway proceeds through several steps. Adenosine is converted to adenine, then to hypoxanthine. Guanosine is converted to guanine. Both hypoxanthine and guanine are then acted upon by xanthine oxidase, the enzyme that converts hypoxanthine → xanthine → uric acid, and guanine → xanthine → uric acid. This step is the pharmacologic target of allopurinol and febuxostat, both xanthine oxidase inhibitors.
In most mammals, uricase converts uric acid into allantoin, a more soluble compound that is easily excreted. Humans and other higher primates lost the gene encoding uricase during evolution. As a result, uric acid is the final excretable product, and humans are uniquely susceptible to hyperuricemia and gout.
Hyperuricemia: definition and causes
Hyperuricemia is defined as serum uric acid above 6.8 mg/dL — the physiologic saturation point at which MSU crystals begin to form in body fluids at 37°C. Note that the clinical threshold used differs slightly by sex in some references: conventionally stated as greater than 7.0 mg/dL in men and greater than 6.0 mg/dL in women, though the crystallization threshold of 6.8 mg/dL applies to all.
Hyperuricemia arises from three mechanisms:
- Overproduction (10% of cases) — excessive dietary purine intake, accelerated cell turnover (hemolytic anemia, myeloproliferative disorders, tumor lysis syndrome, psoriasis), or enzymatic defects (HGPRT deficiency in Lesch-Nyhan syndrome)
- Underexcretion (90% of cases) — impaired renal uric acid clearance due to chronic kidney disease, dehydration, medications (thiazide and loop diuretics, low-dose aspirin, cyclosporine, niacin, pyrazinamide, ethambutol), lead nephropathy, or insulin resistance
- Mixed — a combination of both, common in metabolic syndrome
Nursing implications: when reviewing a patient’s medication list, thiazide diuretics and low-dose aspirin are among the most common drug-induced causes of hyperuricemia seen in clinical practice.
Monosodium urate crystal formation and the inflammatory cascade
When uric acid supersaturates the synovial fluid, MSU crystals precipitate and deposit in the joint space, synovial membrane, articular cartilage, and periarticular soft tissues. Several factors promote crystallization in peripheral joints: lower temperature (explaining why the first MTP joint — farthest from the core — is most affected), lower pH, and reduced protein binding capacity.
Once crystals form, the inflammatory cascade is rapid. MSU crystals are phagocytosed by resident macrophages and neutrophils. This triggers activation of the NLRP3 inflammasome, which processes pro-IL-1β into its active form — interleukin-1 beta (IL-1β). IL-1β is the master cytokine driving gouty inflammation. It stimulates neutrophil influx into the joint in massive numbers, generating reactive oxygen species, lysosomal enzyme release, and prostaglandin synthesis. The result is the intense erythema, warmth, swelling, and exquisite tenderness that characterizes an acute gout flare.
The pain can be so severe that even the weight of a bedsheet on the affected joint is intolerable — this clinical detail appears frequently in NCLEX scenarios.
Stages of gout
| Stage | Characteristics | Serum uric acid | Clinical features |
|---|---|---|---|
| Asymptomatic hyperuricemia | Elevated uric acid; no symptoms; crystals may be forming silently | Elevated (>6.8 mg/dL) | No joint symptoms; may have silent crystal deposition; not all hyperuricemic individuals develop gout |
| Acute gouty arthritis | Sudden onset inflammatory arthritis; self-limiting; resolves in 7–10 days untreated | Variable — may be normal or even low during flare | Podagra (1st MTP), erythema, warmth, swelling, exquisite tenderness; nocturnal onset; fever possible |
| Intercritical gout | Asymptomatic intervals between flares; crystal deposition continues; next flare is closer | Persistently elevated if untreated | No symptoms; patient feels well; MSU crystals detectable in synovial fluid even between flares |
| Chronic tophaceous gout | Years of uncontrolled hyperuricemia; tophi form; chronic synovitis; joint destruction | Markedly elevated | Palpable tophi (ear helix, olecranon bursa, Achilles tendon, fingers); persistent joint symptoms; deformity; renal involvement |
Clinical presentation
Acute flare characteristics
The classic acute gout flare reaches maximum intensity within 6–12 hours of onset. Key features:
- Podagra: inflammation of the first MTP joint, occurring in approximately 50% of initial attacks and 90% of patients at some point in their disease course
- Nocturnal onset: the majority of flares begin at night or in the early morning, often waking the patient from sleep. This is attributed to relative dehydration, lower overnight temperatures, and reduced cortisol levels during sleep
- Pain quality: described as severe, crushing, or excruciating — patients frequently describe it as the worst pain they have ever experienced
- Local signs: intense erythema (may mimic cellulitis), warmth, and swelling; skin may appear shiny and taut; even light touch or the weight of bedding is painful (hyperalgesia)
- Desquamation: as the flare resolves, the overlying skin may peel — a characteristic that helps distinguish a resolving gout flare from infection
- Fever: low-grade fever is common during acute attacks; high fever should raise concern for septic arthritis, which can coexist with gout
Joint distribution
While podagra is the most recognizable presentation, gout can affect multiple joints, especially in later or recurrent disease:
- First MTP joint — most common; classic podagra
- Ankle — second most commonly affected
- Midfoot (tarsal joints) — common; may be mistaken for plantar fasciitis or tendinitis
- Knee — common in chronic or polyarticular gout
- Wrist and small hand joints — more common in women, particularly those on diuretics
- Olecranon bursa — bursitis with tophi formation
- Achilles tendon — peritendinous tophi
Tophi
Tophi are deposits of MSU crystals surrounded by a chronic inflammatory granulomatous reaction. They represent advanced gout and develop after years of inadequately controlled hyperuricemia. Common locations:
- Helix and antihelix of the ear
- Olecranon bursae
- Extensor surface of the forearm
- Achilles tendon
- Finger pads and proximal interphalangeal joints
- Prepatellar bursa
Tophi are firm, chalky-white, irregular nodules. They may ulcerate and discharge white crystalline material. Large tophi can cause joint deformity, impair function, and become superinfected. Unlike rheumatoid nodules — which are smooth and subcutaneous — tophi tend to be irregular and may have overlying erythema. For nursing students who need to differentiate joint conditions, compare with rheumatoid arthritis nursing and osteoarthritis nursing where tophi are absent.
Diagnosis
Synovial fluid analysis — the gold standard
Joint aspiration with polarized light microscopy of synovial fluid is the definitive diagnostic test for gout. Under compensated polarized light microscopy, MSU crystals appear:
- Needle-shaped (acicular)
- Negatively birefringent — appear yellow when parallel to the compensator axis, blue when perpendicular. This is the opposite of calcium pyrophosphate (CPP) crystals in pseudogout, which are positively birefringent (blue when parallel, yellow when perpendicular)
- Intracellular during acute flares — crystals are seen within neutrophils, confirming active phagocytosis and inflammation
Synovial fluid in gout is inflammatory: white blood cell count typically 10,000–100,000 cells/µL (predominantly neutrophils), cloudy appearance, reduced viscosity. Septic arthritis must be ruled out — bacterial culture and Gram stain are obtained simultaneously.
Serum uric acid: an unreliable acute marker
Serum uric acid is frequently checked but has important limitations. During an acute flare, the inflammatory response triggers IL-6-mediated uricosuria (increased renal excretion of uric acid), which can acutely lower serum levels — sometimes into the normal range. Therefore:
- A normal serum uric acid does NOT exclude gout during an acute attack
- Serum uric acid should be measured 2–4 weeks after the acute flare resolves for baseline assessment
- Repeated elevated values on multiple occasions are more meaningful than a single measurement
For nursing students reviewing lab values, this is a high-yield NCLEX concept: do not dismiss gout because the uric acid is normal during the acute flare.
Imaging
Plain radiography (X-ray):
- Early gout: often normal or shows soft tissue swelling
- Late gout (after years): characteristic “rat bite” or “punched-out” erosions with overhanging edges (the Martel sign) — bony erosions at the joint margins with a sclerotic border and overhanging cortex. This appearance distinguishes gouty erosions from the marginal erosions of rheumatoid arthritis
Dual-energy CT (DECT):
- Can detect MSU crystal deposits as a color-coded map (urate deposits appear green)
- Useful when joint aspiration is not feasible or inconclusive
- Most sensitive non-invasive test for crystal deposition
Ultrasound:
- Can detect the double contour sign — a hyperechoic line over cartilage surface due to MSU crystal coating
- Useful for detecting tophi and guiding joint aspiration
Lab values in gout
| Lab test | Normal range | Significance in gout |
|---|---|---|
| Serum uric acid | 2.4–6.0 mg/dL (women); 3.4–7.0 mg/dL (men) | Elevated in chronic hyperuricemia; may be normal during acute flare — does NOT rule out gout |
| BMP — serum creatinine | 0.6–1.2 mg/dL (women); 0.7–1.3 mg/dL (men) | Critical for allopurinol dosing — dose must be reduced in renal impairment; CKD worsens hyperuricemia |
| BMP — eGFR | >60 mL/min/1.73 m² | eGFR <30 → colchicine and NSAIDs require dose reduction or avoidance; affects ULT choice |
| CBC | WBC 4,500–11,000/µL | Leukocytosis during acute flare; elevated WBC in synovial fluid differentiates from non-inflammatory arthritis |
| ESR | 0–20 mm/hr (men); 0–30 mm/hr (women) | Elevated during acute flare; non-specific marker of inflammation |
| CRP | <1.0 mg/dL (<10 mg/L) | Significantly elevated during flare; more specific than ESR; used to monitor treatment response |
| Urinalysis | pH 4.5–8.0; no crystals | Uric acid crystals in urine suggest overproduction; 24-hour uric acid excretion helps classify overproducer vs underexcreter; acidic urine increases risk of uric acid nephrolithiasis |
| 24-hour urine uric acid | <800 mg/day | Overproducers (>800 mg/day) — allopurinol preferred; underexcreters (<800 mg/day) — probenecid may be considered |
For a comprehensive review of laboratory reference ranges and their clinical interpretation, see the nursing lab values cheat sheet.
Nursing assessment
Pain assessment (PQRST)
Use the PQRST framework to characterize acute gout pain:
- P (Precipitating/Palliating): precipitated by dietary indiscretion (shellfish, red meat, beer), dehydration, trauma, surgery, severe illness, contrast media, thiazide initiation, or ULT initiation. Partially palliated by ice application and joint elevation
- Q (Quality): crushing, burning, excruciating; patients often struggle to find words for its severity
- R (Region/Radiation): typically monoarticular at onset; first MTP joint most common; can be ankle, knee, wrist; rarely radiates beyond the affected joint
- S (Severity): often 8–10/10 on numerical rating scale; may be the worst pain the patient reports ever experiencing
- T (Timing): acute onset, reaching peak intensity within hours; nocturnal onset is classic; untreated flare resolves in 7–14 days; treated flares resolve in 1–3 days
Joint examination
- Observe for erythema, swelling, and warmth — the hallmark triad of acute gout
- Assess range of motion — severely restricted and painful during flare
- Note skin changes — shiny, taut skin overlying swollen joint; desquamation as flare resolves
- Palpate for tophi at ear helices, olecranon bursae, Achilles tendons, and finger joints
- Compare bilateral joint findings — gout is typically monoarticular initially; polyarticular gout suggests advanced disease
Tophi assessment
Document each tophus:
- Location (use anatomical landmarks)
- Size (measure in centimeters)
- Consistency (firm, fluctuant if abscess developing)
- Skin integrity (intact, ulcerated, or draining)
- Evidence of superinfection (increased warmth, purulent drainage)
Functional assessment
- Assess ability to bear weight and ambulate
- Evaluate ADL capacity — can the patient dress, bathe, perform activities?
- Assess fall risk, particularly in elderly patients with acute pain affecting weight-bearing joints
- Functional limitations from gout can precipitate deconditioning in hospitalized patients
Medication history — a critical nursing assessment
Screen the full medication list for drugs that raise uric acid levels:
- Thiazide diuretics (hydrochlorothiazide, chlorthalidone) — reduce renal uric acid clearance
- Loop diuretics (furosemide, bumetanide) — volume depletion concentrates uric acid
- Low-dose aspirin (81–325 mg/day) — blocks renal uric acid excretion at low doses (paradoxically, high-dose aspirin is uricosuric)
- Cyclosporine — commonly causes hyperuricemia in transplant recipients
- Niacin — reduces renal uric acid secretion
- Pyrazinamide, ethambutol — anti-tuberculous agents that cause hyperuricemia
- Tacrolimus — similar mechanism to cyclosporine
If a diuretic is being used for hypertension and the patient has recurrent gout, consider discussing with the prescriber whether losartan (an ARB with uricosuric properties) could be substituted — a proactive nursing advocacy opportunity.
Lifestyle and dietary history
Assess:
- Alcohol intake: beer (high in purines + inhibits uric acid excretion), spirits (inhibit excretion), wine (lower risk but still a factor)
- Dietary pattern: frequency of organ meats (liver, kidneys, brain), shellfish (shrimp, lobster, mussels), red meat (beef, pork), fructose-sweetened beverages
- Hydration: daily fluid intake; dehydration concentrates uric acid
- Weight and BMI: obesity is strongly associated with hyperuricemia via insulin resistance-mediated reduced uric acid excretion
- Renal history: prior kidney stones (especially uric acid stones), CKD, family history of gout
Acute flare management
The goals of acute flare management are to relieve pain and inflammation as quickly as possible. Treatment is most effective when started within the first 24 hours of symptom onset. The ACR 2020 guidelines recommend starting pharmacologic therapy within 24 hours.
Drug comparison: acute gout treatment options
| Drug class | Agent/dose | Mechanism of action | Key contraindications | Nursing considerations |
|---|---|---|---|---|
| Colchicine | 0.6 mg PO; repeat 0.6 mg after 1 hour; maximum 1.2 mg per attack (low-dose regimen) | Inhibits microtubule polymerization → blocks neutrophil migration and degranulation → prevents crystal phagocytosis and IL-1β release | Severe renal impairment (eGFR <30); concurrent strong CYP3A4 inhibitors (clarithromycin, cyclosporine — increase colchicine toxicity risk) | GI side effects (diarrhea, nausea, vomiting) are dose-dependent; low-dose regimen (1.2 mg total) as effective as high-dose with less GI toxicity; monitor CBC (rare bone marrow suppression); effective only within first 36 hours of flare onset |
| NSAIDs | Indomethacin 50 mg PO three times daily × 5–7 days; naproxen 750 mg initial dose then 250 mg three times daily; use maximum anti-inflammatory doses | Inhibit COX-1 and COX-2 → reduce prostaglandin synthesis → decrease inflammation and pain | Active GI bleeding or ulcer disease; renal impairment (CrCl <30); heart failure (fluid retention); concurrent anticoagulants (increased bleeding risk); elderly patients (increased GI and renal risk) | Give with food or a PPI; monitor blood pressure (fluid retention); check renal function before and during use; avoid in CHF; highest doses for shortest duration; equally effective to colchicine when initiated promptly |
| Corticosteroids (oral) | Prednisone 40 mg/day × 5 days (or 30–40 mg/day tapering over 10–14 days) | Glucocorticoid receptor-mediated suppression of NF-κB → reduced cytokine production, leukocyte migration inhibition, and prostaglandin synthesis inhibition | Poorly controlled diabetes (steroid hyperglycemia); active infection; systemic fungal infection; active GI ulcer without PPI coverage | Drug of choice when colchicine and NSAIDs are both contraindicated; monitor blood glucose closely in diabetics; do not stop abruptly if using tapers >10 days; equally effective to NSAIDs in randomized trials; intra-articular injection preferred for single-joint involvement |
| Corticosteroids (intra-articular) | Triamcinolone acetonide 10–40 mg intra-articular injection | Same as above; localized delivery reduces systemic effects | Inability to rule out septic arthritis (must aspirate and send for culture/Gram stain first); skin infection overlying joint; joint prosthesis (relative) | Preferred for monoarticular gout when systemic therapy not tolerated; rapid onset; very well tolerated; rule out septic arthritis before injecting corticosteroid into inflamed joint |
| IL-1 inhibitors (reserved/refractory) | Anakinra (off-label), canakinumab (approved in some countries) | Block IL-1β — the master cytokine driving NLRP3 inflammasome-mediated gouty inflammation | Active infection; immunosuppression; reserved for patients who cannot receive colchicine, NSAIDs, or corticosteroids | Specialist-prescribed; subcutaneous injection; monitor for infection; not routine first-line therapy; emerging role in hospitalized patients with multiple comorbidities |
Non-pharmacologic acute management
- Joint rest: avoid weight-bearing on affected joint during acute flare; instruct patient not to walk without assistive devices if lower extremity joint is involved
- Ice application: apply ice pack wrapped in cloth for 20 minutes every 1–2 hours; reduces temperature, pain, and local inflammation; do not apply directly to skin
- Elevation: elevate the affected extremity above heart level to reduce edema and promote fluid drainage
- Cradle protection: use a bed cradle or light blanket support to protect the joint from the weight of bedding — a key nursing intervention for acute podagra
- Hydration: encourage oral fluids (2–3 L/day unless contraindicated) to promote renal uric acid excretion and reduce crystallization risk
Urate-lowering therapy (ULT)
When to initiate ULT
The ACR 2020 guidelines recommend initiating ULT in patients with:
- Two or more gout flares per year
- Any tophi (subcutaneous or on imaging)
- Gout with urate nephropathy or nephrolithiasis
- Gout with stage 2 or higher chronic kidney disease
ULT is never started during an acute flare — doing so can cause further mobilization of crystal deposits and prolong or worsen the current attack. Wait at least 2–4 weeks after the flare resolves. The kidney health implications of hyperuricemia connect to a broader understanding of electrolyte imbalances and renal function.
Allopurinol vs febuxostat
| Feature | Allopurinol | Febuxostat (Uloric) |
|---|---|---|
| Mechanism | Xanthine oxidase inhibitor — reduces uric acid synthesis; both allopurinol and its active metabolite oxypurinol inhibit xanthine oxidase | Selective, non-purine xanthine oxidase inhibitor; more potent inhibition than allopurinol at equivalent doses |
| Starting dose | 100 mg/day (50 mg/day in CKD); titrate by 100 mg every 2–5 weeks to target | 40 mg/day; may increase to 80 mg/day if uric acid target not reached after 2 weeks |
| Target serum uric acid | <6.0 mg/dL (<5.0 mg/dL if tophi present) | Same target: <6.0 mg/dL |
| Renal dosing | Required — dose must be reduced based on eGFR; oxypurinol accumulates in CKD → toxicity risk | Can be used without dose adjustment in mild-moderate CKD; advantage over allopurinol in renal impairment |
| Key adverse effects | Hypersensitivity rash; rare Stevens-Johnson syndrome/toxic epidermal necrolysis (especially with HLA-B*5801 genotype); hepatotoxicity; allopurinol hypersensitivity syndrome (AHS) | FDA boxed warning: increased cardiovascular mortality and all-cause mortality vs allopurinol (CARES trial 2018); use with caution in established cardiovascular disease |
| HLA-B*5801 screening | ACR 2020 recommends screening Asian patients (Han Chinese, Korean, Thai) — HLA-B*5801 prevalence 6–8% vs <1% in Europeans; positive result = avoid allopurinol | Not relevant |
| Preferred in | First-line for most patients; preferred when cardiovascular risk is a concern | Alternative when allopurinol not tolerated, contraindicated, or HLA-B*5801 positive; avoid in history of MI or stroke |
| Drug interactions | Azathioprine/6-mercaptopurine (CRITICAL — allopurinol inhibits xanthine oxidase, blocking metabolism → toxicity); warfarin (increased INR); ampicillin (increased rash risk) | Azathioprine/6-mercaptopurine (same interaction — contraindicated); theophylline |
| Cost | Generic available; low cost | Brand-name; higher cost |
Critical nursing point regarding allopurinol and azathioprine: patients on azathioprine (for organ transplant, inflammatory bowel disease, or autoimmune conditions) must NEVER receive allopurinol without dose adjustment. Allopurinol blocks xanthine oxidase, the enzyme that metabolizes azathioprine, causing accumulation of 6-mercaptopurine → severe bone marrow suppression. If both drugs are necessary, azathioprine dose must be reduced by 50–75% and CBC monitored closely.
Uricosuric agents: probenecid
Probenecid inhibits URAT1, the renal transporter responsible for uric acid reabsorption in the proximal tubule, thereby increasing urinary uric acid excretion. It is a second-line option with important limitations:
- Suitable for: underexcreters with normal or near-normal renal function
- Contraindications: overproducers (increased risk of uric acid kidney stones), eGFR less than 30–50 mL/min (ineffective), history of nephrolithiasis
- Urine alkalinization: require adequate hydration (2–3 L/day) and consider urine alkalinization (potassium citrate) to prevent uric acid stone formation
- Avoid aspirin: low-dose aspirin blocks probenecid’s uricosuric effect
Prophylaxis during ULT initiation
Starting ULT mobilizes existing MSU crystal deposits, releasing crystals into the joint space and triggering additional flares. This is an expected pharmacologic effect — it does NOT mean the medication is failing. The ACR 2020 guidelines recommend colchicine 0.6 mg once or twice daily as flare prophylaxis for 3–6 months after initiating ULT (or until the uric acid target is achieved and stable for 6 months). NSAIDs or low-dose prednisone can be substituted if colchicine is not tolerated.
The ULT paradox — a critical patient education point: Many patients experience a flare shortly after starting allopurinol and, believing the drug is causing harm, stop it. This leads to a cycle of undertreated gout. Nurses play a critical role in preemptively explaining this phenomenon. See the patient education section below.
For pharmacology students, the mechanisms of urate-lowering drugs are covered in depth in the pharmacology nursing reference.
Nursing diagnoses and interventions
| Nursing diagnosis | Related to | Nursing interventions | Expected outcomes |
|---|---|---|---|
| Acute pain | MSU crystal-induced inflammatory response; joint swelling and pressure | Assess pain using PQRST q4h and prn; administer analgesics and anti-inflammatory medications as ordered; apply ice pack (20 min on/off); elevate affected extremity; use bed cradle to prevent sheet contact; position joint in comfort position; teach patient to report pain >7/10 or inadequate relief | Patient reports pain ≤4/10 within 24–48 hours; able to sleep without disruption from joint pain |
| Impaired physical mobility | Joint pain; swelling limiting range of motion; fear of movement exacerbating pain | Assist with ADLs during acute phase; provide assistive devices (crutches, cane, walker) for ambulation if lower extremity affected; collaborate with physical therapy; encourage gradual weight-bearing as flare resolves; fall prevention measures (call light, non-slip footwear, clear pathway) | Maintains skin integrity; ambulates safely with assistive device; regains functional mobility within 1–2 weeks of flare resolution |
| Deficient knowledge: disease management | Unfamiliarity with gout pathophysiology; lack of knowledge regarding ULT adherence and dietary modifications | Teach pathophysiology in lay terms (uric acid crystals = "gravel in the joint"); explain the ULT paradox (flares on initiation are expected — do not stop medication); teach dietary modifications; hydration goals (2–3 L/day); provide written materials; assess health literacy; use teach-back method to confirm understanding | Patient accurately explains why ULT must be continued even during a flare; identifies 3 high-purine foods to limit; states daily fluid goal |
| Risk for injury | Altered gait from acute pain; assistive devices; fall risk from mobility impairment | Complete fall risk assessment (Morse Fall Scale); implement fall precautions; ensure call light in reach; orient to environment; non-slip footwear; bed in lowest position; accompany to bathroom; apply bed alarm if indicated | No falls during hospitalization; patient demonstrates safe use of assistive devices |
| Imbalanced nutrition: more than body requirements | High intake of purine-rich foods and alcohol contributing to hyperuricemia | Assess 24-hour dietary recall; identify specific purine-rich foods the patient consumes regularly; provide dietary education (high-purine vs low-purine foods); involve dietitian; discuss alcohol reduction; address weight management; provide culturally appropriate alternatives for high-purine foods common in the patient's diet | Patient identifies high-purine foods to limit; demonstrates understanding of dietary modifications to reduce gout flares |
| Ineffective self-health management | Inadequate adherence to ULT; misunderstanding of medication purpose; barriers to follow-up care | Assess medication adherence at every visit; review the difference between acute flare medications (short-term) and ULT (chronic, daily, even when asymptomatic); address barriers (cost, side effects, forgetting); encourage monitoring of uric acid levels to reinforce adherence; provide information on patient assistance programs | Patient demonstrates correct medication administration and states rationale for continuing ULT between flares |
Dietary education for gout
Dietary modification can reduce serum uric acid by approximately 1.0–2.0 mg/dL — meaningful but usually insufficient on its own to reach the target of less than 6.0 mg/dL. Diet is a critical component of the overall management strategy, particularly for preventing flares and supporting ULT.
| Category | Foods to limit or avoid | Foods to encourage | Notes |
|---|---|---|---|
| Very high purine — avoid | Organ meats (liver, kidneys, brain, sweetbreads), anchovies, sardines, herring, mackerel, scallops, mussels | — | These can raise serum uric acid by 1–2 mg/dL; strongly associated with acute flare precipitation |
| High purine — limit | Red meat (beef, pork, lamb), shellfish (shrimp, lobster, crab), wild game, goose, turkey, duck | Lean poultry (chicken, turkey — moderate portions), eggs (low in purines) | Limit red meat to 4–6 oz per serving; no more than 4–6 oz lean meat daily overall |
| Alcohol — limit or avoid | Beer (highest risk — contains guanosine purines AND inhibits renal uric acid excretion); spirits (inhibit excretion); wine (lower risk but not risk-free) | Non-alcoholic beverages; sparkling water; herbal teas | Beer is the strongest dietary predictor of gout flares; alcohol of any type increases flare risk; abstinence during flares |
| Fructose — limit | Fructose-sweetened beverages (soda, fruit juices with added HFCS), corn syrup-sweetened foods | Water, unsweetened beverages, coffee (2–4 cups/day associated with lower uric acid) | Fructose stimulates endogenous purine synthesis and impairs renal uric acid excretion; second strongest dietary predictor after alcohol |
| Dairy — encourage | Full-fat dairy (higher purine content, though still modest) | Low-fat or non-fat dairy (skim milk, low-fat yogurt) — strongly protective; associated with lower serum uric acid and reduced flare frequency | Low-fat dairy proteins (casein and lactalbumin) promote renal uric acid excretion; mechanism distinct from purine content |
| Protective foods | — | Cherries and cherry juice (reduce flare risk ~35% per epidemiologic data — anthocyanins inhibit xanthine oxidase and have anti-inflammatory effects); vitamin C 500 mg/day supplement (modest uricosuric effect); coffee (4+ cups/day associated with lower uric acid in epidemiologic studies) | Cherry consumption 2 days before and 2 days after flare most studied; not a replacement for ULT but a useful adjunct |
| Vegetables — reassure | — | Purine-rich vegetables (asparagus, spinach, mushrooms, peas, cauliflower) are acceptable — epidemiologic studies show vegetable purines do NOT increase gout risk | An important patient education point: vegetable purines behave differently from animal purines and need not be restricted |
| Hydration | — | 2–3 L of water per day; increases renal uric acid excretion; dilutes urine to reduce nephrolithiasis risk | Dehydration is a common precipitant of acute flares; especially important during illness, surgery, or hot weather |
Differential diagnosis: gout vs pseudogout vs rheumatoid arthritis
| Feature | Gout | Pseudogout (CPPD) | Rheumatoid arthritis |
|---|---|---|---|
| Crystal type | Monosodium urate (MSU) | Calcium pyrophosphate dihydrate (CPP) | No crystals (autoimmune synovitis) |
| Crystal appearance (polarized light) | Needle-shaped; negatively birefringent (yellow when parallel to compensator) | Rhomboid or rod-shaped; positively birefringent (blue when parallel to compensator) | No crystals in synovial fluid |
| Typical joints | First MTP joint (podagra), ankle, midfoot, knee; usually monoarticular initially | Knee most common; wrist, ankle; larger joints; rarely first MTP | Symmetric small joints (MCP, PIP, wrist); spares DIP joints |
| Onset | Acute, explosive onset; reaches peak within 6–12 hours; nocturnal onset common | Acute or chronic; "pseudogout attack" can mimic gout acutely | Insidious onset; gradual progression; symmetrical involvement |
| Morning stiffness | Minimal between flares; affected joint stiff during flare | Variable | Greater than 1 hour (hallmark) — key NCLEX distinction vs OA (<30 min) |
| Key labs | Serum uric acid (often elevated); ESR/CRP elevated during flare; RF negative; anti-CCP negative | Uric acid normal; calcium/phosphate/magnesium abnormalities (check for metabolic causes — hyperparathyroidism, hemochromatosis); RF negative | RF positive (70–80%); anti-CCP positive (most specific, 95–98%); ESR/CRP elevated; anemia of chronic disease |
| Radiographic findings | "Rat bite" erosions with overhanging edges (late); chondrocalcinosis absent | Chondrocalcinosis (calcification of cartilage, especially knee meniscus) on X-ray | Periarticular osteopenia; marginal erosions; joint space narrowing (symmetric) |
| Tophi | Present in chronic tophaceous gout (ear helix, olecranon bursa, Achilles) | Absent | Rheumatoid nodules (smooth, subcutaneous — different from tophi); no tophi |
| Treatment of acute attack | Colchicine, NSAIDs, corticosteroids | NSAIDs, colchicine, intra-articular corticosteroids (same as gout acutely) | NSAIDs, corticosteroids (short-term); DMARDs (methotrexate) for chronic disease |
| Long-term treatment | Urate-lowering therapy (allopurinol, febuxostat); dietary modification | No ULT equivalent; treat underlying metabolic disorder if identified | DMARDs (methotrexate first-line); biologics (TNF inhibitors, IL-6 inhibitors); folic acid supplementation with methotrexate |
For a detailed comparison with rheumatoid arthritis, see the rheumatoid arthritis nursing reference. For osteoarthritis comparison, see osteoarthritis nursing.
Patient education
Teaching the ULT paradox
This is the single most important patient education point in gout management. When patients start allopurinol or febuxostat, crystal deposits begin to dissolve. Releasing MSU crystals from stable deposits into the synovial fluid provokes new inflammatory episodes. Therefore, starting ULT frequently causes gout flares during the first 3–6 months.
Patients who are not warned about this will commonly:
- Experience a flare while on allopurinol
- Conclude that allopurinol “caused” or “made their gout worse”
- Stop the medication
- Remain in a cycle of recurrent flares without ever achieving adequate urate control
Teach-back script for nurses: “Your allopurinol is working correctly if you get a flare in the first few months. This is because the medicine is dissolving old crystal deposits, and those crystals can irritate the joint while they’re being cleared. The colchicine I am prescribing protects you during this clearing phase. Even if you have a flare, continue taking your allopurinol — stopping it will not help and will delay your long-term recovery. Once your uric acid is controlled for 6 months, flares become much less frequent.”
Hydration teaching
- Target 2–3 L (8–12 cups) of water daily
- Increase intake during hot weather, vigorous exercise, and illness — all dehydration states that concentrate uric acid and precipitate flares
- Avoid dehydration before and after elective surgery
- Limit fructose-sweetened beverages and alcohol
- Coffee (2–4 cups/day) is acceptable and may be mildly protective
Medication adherence
- ULT (allopurinol, febuxostat) must be taken daily, every day — even when asymptomatic and between flares
- ULT does not treat an acute flare — it prevents future ones by gradually lowering the uric acid pool
- Colchicine during ULT initiation is prophylactic, not a treatment — take as prescribed even without symptoms
- Report any rash with allopurinol immediately — a rash may be the first sign of allopurinol hypersensitivity syndrome, which can progress to Stevens-Johnson syndrome
- Patients on allopurinol should understand the azathioprine interaction if they are ever prescribed that drug
Weight management
Obesity contributes to hyperuricemia via insulin resistance, which reduces renal uric acid excretion. Weight loss of 5–10% has been shown to meaningfully reduce serum uric acid levels and flare frequency. However, crash dieting should be avoided — rapid weight loss increases purine load from accelerated cell catabolism and can precipitate a gout flare.
Recognizing when to seek care
Instruct patients to seek immediate care for:
- Fever greater than 38.5°C (101.3°F) with an acutely swollen joint — may indicate septic arthritis, which is a medical emergency requiring immediate joint aspiration and empiric antibiotics
- Flare symptoms that do not improve after 3–5 days of treatment
- New tophi, tophi that become warm/erythematous/tender (risk of superinfection)
- Any skin rash after starting allopurinol
Differentiating septic arthritis from an acute gout flare is covered in the sepsis nursing reference in the context of infectious presentations.
Complications
Urate nephropathy
Chronic hyperuricemia can cause two forms of renal injury:
- Uric acid nephropathy (acute): massive uric acid release (tumor lysis syndrome, rhabdomyolysis) precipitates uric acid crystals in renal tubules → oliguric acute kidney injury. Prevention: aggressive hydration, urinary alkalinization, rasburicase or allopurinol in high-risk patients
- Gouty nephropathy (chronic): years of MSU crystal deposition in renal interstitium → chronic interstitial nephritis → progressive CKD. This complication reinforces the importance of achieving serum uric acid targets through ULT
Renal complications of gout are closely related to the pathophysiology discussed in the AKI nursing reference and the CKD nursing reference.
Nephrolithiasis
Uric acid kidney stones account for approximately 5–10% of all kidney stones. Risk factors:
- Persistently acidic urine (pH less than 5.5) — uric acid is insoluble in acidic urine
- High uric acid excretion (overproducers)
- Low urine volume (chronic dehydration)
- Concurrent hyperuricemia
Uric acid stones are radiolucent on plain X-ray (unlike calcium oxalate stones, which are radiopaque) but visible on CT. Treatment includes urinary alkalinization with potassium citrate (target urine pH 6.0–6.5), hydration, and allopurinol for overproducers.
Chronic tophaceous gout
Untreated or undertreated gout progresses over years to decade-long courses of crystal deposition. Consequences:
- Tophi in periarticular soft tissues, tendons, and bursae
- Chronic synovitis with persistent low-grade joint pain between flares
- Destructive arthropathy with joint deformity and functional disability — similar mechanically to damage seen in osteoporosis-related joint disease discussed in the osteoporosis nursing reference
- Tophi that ulcerate and superinfect
- Spinal involvement (rare but serious — can compress spinal cord or nerve roots)
Cardiovascular risk
Gout is independently associated with increased cardiovascular risk — approximately 1.6-fold increased risk of major adverse cardiovascular events. The mechanisms include:
- Hyperuricemia itself may promote oxidative stress and endothelial dysfunction
- Systemic inflammation during recurrent flares
- Shared risk factors (hypertension, metabolic syndrome, CKD, obesity)
- NSAIDs used for flares carry cardiovascular risk with chronic use
This cardiovascular connection means nurses managing gout patients should ensure hypertension, dyslipidemia, and diabetes are adequately controlled — a holistic approach to secondary cardiovascular prevention.
NCLEX-style practice questions
For additional test-taking strategies applicable to these questions, review the NCLEX study tips reference.
Question 1
A patient presents to the emergency department at 3 AM with sudden severe pain (10/10) in the right great toe, which has been red, warm, and swollen for 4 hours. Serum uric acid is 5.9 mg/dL. Which of the following is the correct interpretation?
A) Gout is ruled out because the serum uric acid is within normal limits B) The patient likely has cellulitis given the erythema and warmth C) A normal serum uric acid during an acute attack does not exclude gout D) The patient should be started on allopurinol immediately
Answer: C
Rationale: Serum uric acid frequently falls to normal or low levels during an acute gout attack due to IL-6-mediated uricosuria. A normal result does NOT exclude gout. (A) is incorrect — this is the most dangerous misconception to hold. (B) is possible but the nocturnal, sudden-onset, single-joint presentation is classic for gout. (D) is incorrect — ULT is never initiated during an acute flare; it should be started 2–4 weeks after resolution.
Question 2
A patient with gout is started on allopurinol 100 mg daily. Three weeks later, he calls the clinic reporting a new gout flare and states he has stopped taking the allopurinol. Which nursing response is most appropriate?
A) “You were correct to stop it — allopurinol can worsen acute gout attacks” B) “Restart the allopurinol immediately and take a double dose to make up for the missed days” C) “Flares during the first few months of starting allopurinol are expected and do not mean the drug is causing harm — please restart it” D) “Switch to febuxostat, which does not cause this effect”
Answer: C
Rationale: ULT initiation mobilizes existing crystal deposits, which can trigger flares during the first 3–6 months — this is expected and does not indicate treatment failure. The patient should restart allopurinol. (A) is incorrect and dangerous patient counseling. (B) is incorrect — doubling up doses is not recommended. (D) is incorrect — febuxostat causes the same phenomenon.
Question 3
The nurse is preparing a patient with gout for discharge. Which dietary instruction is most accurate?
A) “Avoid all vegetables high in purines, including spinach, asparagus, and mushrooms” B) “Drink at least 2–3 liters of water daily and limit alcohol, particularly beer” C) “Low-fat dairy should be avoided as it contains protein that increases uric acid” D) “Coffee should be avoided because caffeine raises uric acid levels”
Answer: B
Rationale: Adequate hydration promotes renal uric acid excretion and reduces crystal formation. Beer is the strongest dietary precipitant of gout flares due to its purine content and urate excretion-inhibiting effect. (A) is incorrect — vegetable purines do NOT increase gout risk; vegetables need not be restricted. (C) is incorrect — low-fat dairy is protective; its proteins promote urinary uric acid excretion. (D) is incorrect — epidemiologic studies show coffee consumption is associated with lower serum uric acid levels.
Question 4
A patient with gout is prescribed allopurinol. The nurse reviews the medication list and finds the patient is also taking azathioprine for Crohn’s disease. Which action should the nurse take first?
A) Administer the allopurinol as prescribed; there are no significant interactions B) Hold both medications and notify the physician of the potential drug interaction C) Administer the allopurinol but monitor the CBC closely D) Substitute colchicine for allopurinol to avoid the interaction
Answer: B
Rationale: Allopurinol inhibits xanthine oxidase, which is responsible for metabolizing azathioprine (and its active metabolite 6-mercaptopurine). Concurrent use without dose adjustment leads to azathioprine accumulation and potentially fatal bone marrow suppression. The prescriber must be notified immediately before the first dose is given. (A) is incorrect and dangerous. (C) is insufficient action — the prescriber must be involved. (D) is incorrect framing — substituting gout medications without addressing the combination is not the first action.
Question 5
The nurse is caring for a patient with suspected gout affecting the knee. The physician orders a joint aspiration. Under polarized light microscopy, which finding confirms the diagnosis of gout (rather than pseudogout)?
A) Positively birefringent rhomboid-shaped crystals B) Negatively birefringent needle-shaped crystals C) Gram-positive cocci in clusters within leukocytes D) Turbid fluid with WBC count of 120,000/µL
Answer: B
Rationale: MSU crystals in gout appear needle-shaped and negatively birefringent under compensated polarized light — yellow when aligned parallel to the compensator axis, blue when perpendicular. (A) describes calcium pyrophosphate crystals seen in pseudogout (positively birefringent, rhomboid). (C) describes septic arthritis (Staphylococcus aureus); while septic arthritis must always be ruled out, this does not confirm gout. (D) — a WBC of 120,000/µL is more consistent with septic arthritis than gout (gout WBC typically 10,000–100,000/µL).
Question 6
A patient with gout and stage 3 CKD (eGFR 35 mL/min) has an acute flare of the knee. Which medication is MOST appropriate for managing this acute flare?
A) Indomethacin 50 mg three times daily for 7 days B) Colchicine 0.6 mg, repeat in 1 hour; maximum 1.2 mg C) Prednisone 40 mg/day for 5 days D) Begin allopurinol 100 mg daily to lower uric acid levels
Answer: C
Rationale: In a patient with stage 3 CKD (eGFR 35 mL/min), both NSAIDs and colchicine require significant caution or dose reduction. NSAIDs (A) are relatively contraindicated in moderate-severe CKD due to risk of acute kidney injury and fluid retention. Colchicine (B) should be used with dose reduction in eGFR 30–60 and avoided with eGFR <30 — at eGFR 35, it requires caution and a single-dose low-dose regimen only; standard dosing is risky. Corticosteroids (C) are the safest choice in significant renal impairment and are the preferred acute treatment when NSAIDs and colchicine are contraindicated. (D) is incorrect — ULT is never started during an acute flare.
Summary
Gout is a chronic metabolic disease that nurses encounter frequently across all care settings. The acute flare — particularly podagra — is dramatic and responds well to rapid pharmacologic treatment. Long-term control requires sustained urate-lowering therapy with a target serum uric acid below 6.0 mg/dL, combined with dietary modification, hydration, and medication adherence.
The most common failure modes in gout management are stopping ULT during the early flare-mobilization period (the ULT paradox), inadequate hydration, and failure to address drug-induced hyperuricemia. Nurses who understand these failure modes are in the best position to prevent them through proactive patient education, targeted medication reconciliation, and individualized dietary counseling.
The differential diagnosis — particularly distinguishing gout from pseudogout and septic arthritis — depends on synovial fluid analysis. Nurses who understand crystal birefringence characteristics can interpret these results meaningfully and contribute to timely diagnosis.
For related musculoskeletal content, see the complete cluster: osteoporosis, rheumatoid arthritis, and osteoarthritis.